Stelara the new treatment for Psoriasis has succesfully completed clinical trials and has now been licensed and FDA approved for the treatment of acute psoriasis. Stelara is a monoclonal antibody therapy which is given as a monthly 45 mg subcutaneous injection. The ACCEPT clinical trials showed that Stelara (aka Ustekinumab) effectively treated psoriasis with minimal side effects. Stelara has been designed as a very selective form of therapy specifically targetting IL-12 which is involved in psoriasis plaque formation. By selectively targetting IL-12 Stelara is able to exert its effects aginst psoriasis withou causing any other side effects.
Stelara, Zytiga, and Xarelto are 3 new bockbuster drugs from health giant Johnson & Johnson who know a good drug when they see one, and have selected key drugs in there respective clinical settings. Stelara has unique activity against psoriasis, Zytiga is highly effective against advanced prostate cancer, and Xarelto is an effective anticoagulant used to prevent strokes.
No comments:
Post a Comment